Navigation Links
Bionovo Announces Publication Describing How Metabolic Adaptability Contributes to the Metastasis of Tumors
Date:12/15/2010

EMERYVILLE, Calif., Dec. 15, 2010 /PRNewswire/ -- Bionovo, Inc. (Nasdaq: BNVI) today announced the publication of a study entitled "CC3/TIP30 regulates metabolic adaptation of tumor cells to glucose limitation" in the journal Cell Cycle. The study describes the critical linkage between the expression of the protein CC3/TIP30 in cancer cells and their ability to adapt and survive in adverse conditions such as lack of glucose and other nutrients. Lack of CC3/TIP30 in a variety of human tumors allows them to resist the death signals created by metabolic stress encountered during aggressive tumor growth and metastases. Absence of CC3/TIP30 thus contributes to the development of aggressive and metastatic cancers.

"The research described in this publication is a result of a long standing interest in the metabolic changes accompanying the development of aggressive cancers. Metabolism has recently become the focus of intense interest in the basic and translational cancer research," said Emma Shtivelman, Ph.D., Director of Cancer Research at Bionovo. "We found that a previously discovered metastasis suppressor CC3/TIP30 affects tumor cell metabolism in unexpected ways. Expression of CC3/TIP30 is low or even absent in a variety of advanced cancers. Our work shows that absence of CC3 contributes to survival of tumor cells under adverse conditions such as lack of nutrients. Tumor cells, in particular metastatic cells, frequently encounter conditions of low glucose availability due to inadequate blood supply. Absence of CC3 allows tumor cells to modify their metabolic preferences and relinquish their dependence on glucose for glycolytic energy production. Cells lacking CC3 adapt to low glucose conditions by activating mitochondrial respiration and oxidative phosphorylation, and continue to survive and proliferate. Cells expressing CC3/TIP30 fail to adapt to limited availability of glucose, and succumb to cell death. Therefore, silencing of CC3/TIP30 expression in aggressive and metastatic cancers provides metabolic flexibility and a survival advantage under adverse conditions."

"The long-known Warburg effect postulates that cancer cells, unlike most normal cells, rely heavily on glycolysis, a process utilizing sugar for energy production, and have dispensed with the normal mitochondrial process, oxidative phosphorylation, utilizing oxygen for energy production," said Isaac Cohen, O.M.D., Bionovo's Chairman and Chief Executive Officer. "Dr. Shtivelman's discovery contributes to our understanding that tumor cells have increased metabolic demands, and could employ a variety of metabolic pathways to support their increased abnormal growth and proliferation. This work was supported by a RO1 grant from the National Cancer Institute to Dr. Shtivelman. Bionovo has been committed to the development of drugs that disrupt these metabolic paths and result in selectively targeting cancer cells while sparing normal cells."

About Bionovo, Inc.

Bionovo, Inc. is a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, markets with significant unmet needs and billions in potential annual revenue. The company applies its expertise in the biology of menopause and cancer to design new drugs derived from botanical sources, which have novel mechanisms of action. Based on the results of early and mid-stage clinical trials, Bionovo believes it has discovered new classes of drug candidates within its rich pipeline with the potential to be leaders in their markets. Bionovo is headquartered in Emeryville, California and its stock is traded on the NASDAQ Capital Market under the symbol "BNVI." For more information about Bionovo and its programs, visit http://www.bionovo.com.

Forward Looking Statements

This release contains certain forward-looking statements relating to the business of Bionovo, Inc. that can be identified by the use of forward-looking terminology such as "believes," "expects," or similar expressions. Such forward-looking statements involve known and unknown risks and uncertainties, including uncertainties relating to product development, efficacy and safety, regulatory actions or delays, the ability to obtain or maintain patent or other proprietary intellectual property protection, market acceptance, physician acceptance, third party reimbursement, future capital requirements, competition in general and other factors that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. Certain of these risks and uncertainties are or will be described in greater detail in our filings with the Securities and Exchange Commission, which are available at http://www.sec.gov. Bionovo, Inc. is under no obligation (and expressly disclaims any such obligation) to update or alter its forward-looking statements whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Bionovo, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Bionovo Releases FDA-Approved Clinical Development Plan for Menerba
2. Bionovo Announces Publication Describing Estrogen Receptor Beta Cancer Prevention Mechanism
3. Bionovo Announces Third Quarter 2010 Highlights and Financial Results
4. Bionovo, Inc. to Announce Third Quarter Fiscal Year 2010 Financial Results on Thursday, November 11, 2010
5. Bionovo Announces Publication Describing Potential Estrogen Receptor Modulating Drugs for Treating Menopausal Conditions
6. Bionovo to Raise $3 Million Through Registered Direct Offering
7. Bionovo to Present at the JMP Securities Healthcare Conference
8. Bionovo to Present at Cambria Capital Investor Meeting
9. Bionovo Receives Positive Guidance from FDA on Menerba®
10. Bionovo Announces Reverse Stock Split
11. Bionovo Announces Publication Describing Menerbas Effect on Neural Pathways Related to Temperature Regulation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/12/2017)... Kineta, Inc., a biotechnology company focused on the development of ... R&D and Head of Virology Kristin Bedard has been invited ... and Beyond meeting sponsored by Life Science Washington.  This ... AM PDT at the Agora Conference Center in ... be joined by other leaders in infectious disease research and ...
(Date:6/9/2017)... , June 9, 2017 More than ... further effort to help spread lessons learned from clinical ... International Diabetes Federation (IDF) and Eli Lilly and Company ... the second phase of the Bringing Research in Diabetes ... their commitment to helping people with diabetes effectively manage ...
(Date:6/7/2017)... , June 7, 2017 Endo International ... June 7, 2017, the Hon. Joseph R. Goodwin ... of West Virginia , entered a ... Inc. Pelvic Repair System Products Liability Litigation (the "MDL") ... MDL cases to provide expert disclosures on specific causation ...
Breaking Medicine Technology:
(Date:6/28/2017)... ... June 28, 2017 , ... Hayes, Inc., a leading ... the guest speaker lineup* for its second annual Client Symposium. Joining the symposium ... Dr. Keith Fernandez of Privia Health; and Lisa Tourville of Anthem. , ...
(Date:6/28/2017)... ... ... American Farmer proudly announces the participation of Pure Line Seeds, Inc (Pure Line ... fourth quarter 2017. American Farmer airs Tuesdays at 8:30aET on RFD-TV. , Founded in ... demand grew, the small company located in Moscow, Idaho extended its sales from Northern ...
(Date:6/28/2017)... ... June 28, 2017 , ... Designers Insurance ... communities in northern Virginia and DC, is announcing a cooperative charity event in ... Alzheimer’s and other disorders that lead to memory impairment. , The Insight Memory ...
(Date:6/27/2017)... ... ... Harbour , a DAO (decentralized autonomous organization) that harnesses the wisdom of ... technical specifications . , 2017 has seen an explosion of token launches by blockchain ... will garner the greatest ROI. Dean Eigenmann, Co-founder and CEO of Harbour, said, “We ...
(Date:6/27/2017)... (PRWEB) , ... June 27, 2017 , ... A January ... been projected to reach a staggering $6.81 billion by the year 2024 according to ... at a faster rate than those made from titanium. Los Angeles area clinic Beverly ...
Breaking Medicine News(10 mins):